ReviewTurk psikiyatri dergisi = Turkish journal of psychiatry2025
Off-label Prescribing of Clozapine and Safety.
Review in Turk psikiyatri dergisi = Turkish journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clozapine is a unique antipsychotic primarily indicated for treatmentresistant schizophrenia, recurrent suicidal behavior in schizophrenia or schizoaffective disorder, and psychotic disorders in Parkinson’s disease. It is also prescribed off-label in selected patients with mood disorders, personality disorders, or post-traumatic stress disorder. Despite its efficacy, clozapine is underprescribed due to concerns regarding adverse effects, particularly agranulocytosis. This narrative review aims to summarize the reported results regarding the off-label use of clozapine and analyze the potential risks and benefits of these practices. Offlabel prescribing, which involves using medications for unapproved indications, is common in psychiatry due to the insufficient effectiveness of many approved treatments. Clozapine, even at relatively low doses, has shown potential clinical benefits in patients with bipolar disorder, borderline personality disorder, and post-traumatic stress disorder. However, its off-label use remains limited due to safety concerns. The safety concerns associated with clozapine include agranulocytosis, myocarditis, cardiomyopathy, seizures, and metabolic syndrome. The prevention of agranulocytosis, a severe reduction in white blood cells, requires regular monitoring of blood counts. Myocarditis and cardiomyopathy necessitate careful cardiological monitoring, especially during the first month of treatment. Seizures can occur, particularly at higher doses, and metabolic syndrome, including weight gain, diabetes, and hyperlipidemia, requires ongoing management. Other adverse effects such as constipation, hypersalivation, and sedation can also impact patient compliance and quality of life. Despite these risks, with careful patient selection, individualized dosing, and continuous monitoring, the therapeutic potential of clozapine in off-label indications warrants further exploration in clinical trials. Keywords: Adverse effects, clozapine, mood disorders, off-label prescribing, personality disorders, post-traumatic stress disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.